- Conditions
- Spinal Muscular Atrophy
- Interventions
- 4-aminopyridine, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 58
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Sclerosis, Internuclear Ophthalmoplegia, Fatigue
- Interventions
- Dalfampridine, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Nerve Injury
- Interventions
- 4-Aminopyridine, Placebo oral tablet
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Spinal Cord Injury
- Interventions
- Dalfampridine, Placebo drug, STDP stimulation, Exercise training
- Drug · Other · Behavioral
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Nerve Injury, Prostate Cancer
- Interventions
- 4-Aminopyridine, Placebo
- Drug · Other
- Lead sponsor
- John Elfar
- Other
- Eligibility
- 45 Years to 75 Years · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Rochester, New York
- Conditions
- Myasthenic Syndromes, Congenital
- Interventions
- amifampridine phosphate, Placebo
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Cerebral Palsy (CP)
- Interventions
- dalfampridine-ER 10mg, Placebo
- Drug · Other
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Downey, California • Los Angeles, California + 8 more
- Conditions
- Multiple Sclerosis
- Interventions
- dalfampridine ER, placebo
- Drug
- Lead sponsor
- Brown, Theodore R., M.D., MPH
- Individual
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Kirkland, Washington
- Conditions
- Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2, Spinocerebellar Ataxias Type 3, Spinocerebellar Ataxias Type 6
- Interventions
- Dalfampridine, Placebo
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 33 more
- Conditions
- Lambert Eaton Myasthenic Syndrome (LEMS)
- Interventions
- 3,4-diaminopyridine
- Drug
- Lead sponsor
- Louis H. Weimer, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Disease
- Interventions
- 4-aminopyridine, placebo
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 45 Years to 75 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Amifampridine Phosphate, Placebo Oral Tablet
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Multiple Sclerosis, Fatigue
- Interventions
- Dalfampridine, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 20 Years to 59 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more
- Conditions
- Peripheral Nerve Injury, Crush Injury
- Interventions
- 4-Aminopyridine, Placebo
- Drug · Other
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Lambert Eaton Myasthenic Syndrome
- Interventions
- 3, 4 DAP
- Drug
- Lead sponsor
- David P. Richman, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- SCI - Spinal Cord Injury
- Interventions
- Dalfampridine, Placebo, STDP stimulation, Exercise training
- Drug · Other · Behavioral
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Imatinib, Fampridine
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Burns, Second Degree Burn, Wounds and Injuries
- Interventions
- Drug: 4-Aminopyridine, Placebo
- Drug · Other
- Lead sponsor
- John Elfar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Ischemic Stroke
- Interventions
- placebo/dalfampridine-ER, dalfampridine-ER/placebo
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • La Jolla, California • Newport Beach, California + 17 more
- Conditions
- Congenital Myasthenic Syndrome
- Interventions
- 3,4-Diaminopyridine
- Drug
- Lead sponsor
- Ricardo Maselli
- Other
- Eligibility
- 3 Months to 75 Years
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Myasthenia Gravis, MuSK, AChR Myasthenia Gravis
- Interventions
- Amifampridine Phosphate
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Lambert Eaton Myasthenic Syndrome
- Interventions
- Amifampridine Phosphate, Placebo
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 3 more